Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

AdvaMed Recommends Steps to Strengthen RAPID Pathway for Breakthrough Medical Technologies

8 October 2026 · By · Wire by Fusion42

Published

8 October 2026

Topic

regulatory

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at advamed.org →

◆ Verified

Fusion42 · 9 October 2026 · Fusion42 review

AdvaMed recommended refinements to CMS’s proposed RAPID coverage pathway to accelerate Medicare access to breakthrough medical devices, proposing broader eligibility, clear timelines, and better coordination with FDA regulatory processes.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 8 Oct 2026 and 9 Oct 2026.

◆ ◆ The Wire takeaway

You now have a clearer route to Medicare reimbursement for breakthrough devices in the US. Start engaging CMS and FDA on RAPID pathway details to speed patient access and reduce coverage uncertainty.

◆ Coverage

2 sources · first reported 8 Oct 2026 · latest 9 Oct 2026

◆ Related on Wire

◆ Topics

Medtechmedtechmedicareregulatory-pathwaybreakthrough-devicesCMSFDA